Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.96 USD | +7.72% | +8.53% | +229.02% |
May. 31 | Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 | CI |
May. 20 | Transcript : Jasper Therapeutics, Inc. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 5.5M | Capitalization | 392M |
---|---|---|---|---|---|
Net income 2024 * | -65M | Net income 2025 * | -78M | EV / Sales 2024 * | - |
Net cash position 2024 * | 217M | Net cash position 2025 * | - | EV / Sales 2025 * | 71.2 x |
P/E ratio 2024 * |
-5.84
x | P/E ratio 2025 * |
-6.32
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.39% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | +7.72% | ||
1 week | +8.53% | ||
1 month | +8.21% | ||
3 months | +17.57% | ||
6 months | +315.49% | ||
Current year | +229.02% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 25.96 | +7.72% | 71,315 |
24-05-30 | 24.1 | -0.50% | 105,441 |
24-05-29 | 24.22 | +1.00% | 70,456 |
24-05-28 | 23.98 | +0.25% | 130,035 |
24-05-24 | 23.92 | +0.42% | 143,905 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+229.02% | 392M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- JSPR Stock